natgillin/translations-raw huggingface dataset:
YENTREVE не трябва да се употребява при пациенти с тежко бъбречно увреждане (креатининов клирънс <30 ml/min; вижте точка 4.3).
YENTREVE must not be used in patients with severe renal impairment (creatinine clearance <30 ml/min; see section 4.3).
Yentreve се използва за лечение на умерена до тежка форма на стресова уринарна инконтиненция при жени (SUI).
Yentreve is used to treat moderate to severe stress urinary incontinence (SUI) in women.
Yeonsu-gu, Incheon, 406-840 Република Корея
Yeonsu-gu, Incheon, 406-840 Republic of Korea
YERVOY 5 mg/ml концентрат за инфузионен разтвор
YERVOY 5 mg/ml concentrate for solution for infusion
YERVOY 5 mg/ml концентрат за инфузионен разтвор Ипилимумаб
YERVOY 5 mg/ml concentrate for solution for infusion Ipilimumab
YERVOY 5 mg/ml концентрат за инфузионен разтвор ипилимумаб (ipilimumab)
YERVOY 5 mg/ml concentrate for solution for infusion ipilimumab
YERVOY 5 mg/ml стерилен концентрат Ипилимумаб
YERVOY 5 mg/ml sterile concentrate Ipilimumab
YERVOY действа на Вашата имунна система и може да причини възпаление в някои части на Вашия организъм.
YERVOY acts on your immune system and may cause inflammation in parts of your body.
Yervoy е лекарство, което съдържа активното вещество ипилимумаб (ipilimumab).
Yervoy is a medicine that contains the active substance ipilimumab.
YERVOY е показан за лечение на авансирал меланом (неоперабилен или метастатичен) при възрастни.
YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.
YERVOY инфузията не трябва да се прилага като интравенозна инжекция или болусна инжекция.
The YERVOY infusion must not be administered as an intravenous push or bolus injection.
YERVOY концентрат за инфузионен разтвор е бистър до слабо опалесциращ, безцветен до бледожълт и може да съдържа малко (на брой) частици.
YERVOY concentrate for solution for infusion is clear to slightly opalescent, colourless to pale yellow and may contain light (few) particulates.
YERVOY може да се използва за интравенозно приложение:
YERVOY can be used for intravenous administration either:
YERVOY не трябва да се прилага при деца и юноши под 18-годишна възраст, докато не се получи повече информация.
YERVOY should not be used in children and adolescents below 18 years of age until more information becomes available.
YERVOY не трябва да се прилага при деца и юноши под 18-годишна възраст.
YERVOY should not be used in children and adolescents below 18 years of age.
Yervoy обичайно се свързва с нежелани лекарствени реакции в резултат на ексцесивна имунна активност, включващи тежки реакции и възпаление.
Yervoy is commonly associated with side effects resulting from excessive activity of the immune system, including severe reactions and inflammation.
Yervoy се използва за лечение на възрастни с авансирал меланом (вид рак на кожата, който засяга клетки, наречени меланоцити).
Yervoy is used to treat adults with advanced melanoma (a type of skin cancer affecting cells called melanocytes).
Yervoy се прилага като инфузия във вената за 90 минути.
Yervoy is given as an infusion into a vein over 90 minutes.
YERVOY съдържа активното вещество ипилимумаб – протеин, който помага на Вашата имунна система да атакува и убива ракови клетки чрез имунните клетки.
YERVOY contains the active substance ipilimumab, a protein which helps your immune system to attack and destroy cancer cells by your immune cells.
YERVOY трябва да се прилага с повишено внимание при пациенти с нива на трансаминазите ≥ 5 x ГГН или ниво на билирубина > 3 x ГГН на изходно ниво (вж. точка 5.1).
YERVOY must be administered with caution in patients with transaminase levels ≥ 5 x ULN or bilirubin levels > 3 x ULN at baseline (see section 5.1).
YERVOY ще Ви бъде прилаган един път на 3 седмици – общо 4 дози.
You will be treated with YERVOY once every 3 weeks, for a total of 4 doses.
YERVOY ще Ви се прилага в болница или клиника под наблюдението на лекар специалист.
YERVOY will be given to you in a hospital or clinic under the supervision of an experienced doctor.
YKA3AHl1.s 3A YnOTPE6A
INSTRUCTIONS ON USE
YMDD-mutationen medför resistens mot både emtricitabin och lamivudin.
The YMDD mutation confers resistance to both emtricitabine and lamivudine.
Yondelis
Ovarian cancer
Yondelis 0,25 mg
Yondelis 0.25 mg
Yondelis 0,25 mg prášok na infúzny koncentrát
Yondelis 0.25 mg powder for concentrate for solution for infusion.
Yondelis 0,25 mg prášok na infúzny koncentrát trabektedín
Yondelis 0.25 mg powder for concentrate for solution for infusion Trabectedin
Yondelis 0,25 mg prášok na infúzny koncentrát Yondelis 1 mg prášok na infúzny koncentrát trabektedín
Yondelis 0.25 mg powder for concentrate for solution for infusion Yondelis 1 mg powder for concentrate for solution for infusion Trabectedin
Yondelis 0,25 mg: jedna injekčná liekovka prášku obsahuje 0,25 mg trabektedínu.
Yondelis 0.25 mg: Each vial of powder contains 0.25 mg of trabectedin.
Yondelis 0,25 mg: Vstrieknite 5 ml sterilnej vody pre injekcie do injekčnej liekovky.
Yondelis 0.25 mg: Inject 5 ml of sterile water for injections into the vial.
Yondelis 1 mg prášok na infúzny koncentrát trabektedín
Yondelis 1 mg powder for concentrate for solution for infusion Trabectedin
Yondelis 1 mg prášok na infúzny koncentrát.
Yondelis 1 mg powder for concentrate for solution for infusion.
Yondelis 1 mg: jedna injekčná liekovka prášku obsahuje 1 mg trabektedínu.
Yondelis 1 mg: Each vial of powder contains 1 mg of trabectedin.
Yondelis 1 mg: Vstrieknite 20 ml sterilnej vody pre injekcie do injekčnej liekovky.
Yondelis 1 mg: Inject 20 ml of sterile water for injections into the vial.
Yondelis a alkohol
Yondelis with alcohol
Yondelis alebo jeho kombinácie s PDL sa nesmiú používať, ak trpíte vážnym poškodením pečene, obličiek alebo srdca.
Yondelis or its combination with PLD must not be used if you have severe liver, kidney or cardiac damage.
Yondelis bol podávaný v 6 alebo viacerých cykloch u 29,5 % pacientov liečených monoterapiou a u 52 % pacientov liečeným kombinovanou dávkou a podľa navrhnutého časového plánu.
Yondelis has been administered for 6 or more cycles in 29.5% and 52% of patients treated with the monotherapy and combination dose and schedule respectively.
Yondelis je cytotoxický protirakovinový liečivý výrobok, a rovnako ako u ostatných potenciálne toxických zlúčenín, musí sa pri manipulácii s ním zachovávať opatrnosť.
Yondelis is a cytotoxic anticancer medicinal product and, as with other potentially toxic compounds, caution should be exercised during handling.
Yondelis je protirakovinový liek, ktorý funguje tak, že zabraňuje rozmnožovaniu nádorových buniek.
Yondelis is an anti-cancer medicine that works by preventing the tumour cells from multiplying.
Yondelis je prášok na infúzny koncentrát.
Yondelis is a powder for concentrate for solution for infusion.
Yondelis monoterapia sa nesmie používať u pacientov s klírensom kreatinínu < 30 ml/min a kombinovaný režim sa nesmie používať u pacientov s klírensom kreatinínu < 60 ml/min (pozri časť 4.2).
Yondelis monotherapy and combination regimens must not be used in patients with creatinine clearance < 30 ml/min and < 60 ml/min respectively (see section 4.2).
Yondelis obsahuje draslík
Yondelis contains potassium
Yondelis obsahuje liečivo trabektedín.
Yondelis contains the active substance trabectedin.
Yondelis podávaný v kombinácii s pegylovaným lipozomálnym doxorubicínom (pegylated liposomal doxorubicin, PLD) je indikovaným pre liečbu pacientov s relapsom ovariálneho karcinómu citlivého na platinu.
Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
Yondelis sa musí podávať pod dohľadom lekára, ktorý má skúsenosti s používaním chemoterapie.
Yondelis must be administered under the supervision of a physician experienced in the use of chemotherapy.
Yondelis sa nemá používať počas tehotenstva.
Yondelis should not be used during pregnancy.
Yondelis sa nemá používať u detí mladších ako 18 rokov s pediatrickými sarkómami z dôvodu účinnosti (pozri výsledky štúdie sarkómov u detí v časti 5.1).
Yondelis should not be used in children below 18 years with paediatric sarcomas because of efficacy concerns (see 5.1 for results of paediatric sarcoma study).
Yondelis sa nemá používať u detí mladších ako 18 rokov s pediatrickými sarkómami.
Yondelis should not be used in children below 18 years of age with paediatric sarcomas.
Yondelis sa nesmie miešať ani riediť inými liečivými výrobkami okrem tých, ktoré sú uvedené v časti 6.6.
Yondelis must not be mixed or diluted with other medicinal products except those mentioned in section 6.6.
Yondelis sa nesmie podávať ako zmes s inými liekmi v rovnakej infúzii, s výnimkou riedidla.
Yondelis must not be administered as a mixture with other medicines in the same infusion apart from the diluent.
Yondelis sa nesmie podávať pacientkam, ktoré dojčia.
Yondelis must not be given to patients who are breast-feeding.
Yondelis sa nesmie používať u pacientov so zvýšeným bilirubínom.
Yondelis must not be used in patients with elevated bilirubin.
Yondelis sa pred intrevenóznou infúziou musí rekonštituovať a ďalej nariediť.
Yondelis must be reconstituted and further diluted prior to intravenous infusion.
Yondelis vám bude podaný pod dohľadom lekára, ktorý má skúsenosti s používaním chemoterapie.
Yondelis is given to you under the supervision of a physician experienced in the use of chemotherapy.
Yondelis се използва, когато лечението с антрациклини и ифосфамид (други лекарства за рак) е спряло да действа или при пациенти, на които тези лекарства не могат да бъдат прилагани. овариален рак (рак на яйчника) при рецидив (заболяването се е възобновило след предходно лечение) и чувствителност към лекарства, съдържащи платина.
Yondelis is used when treatment with anthracyclines and ifosfamide (other cancer medicines) have stopped working, or in patients who cannot be given these medicines; ovarian cancer (cancer of the ovaries) that has relapsed (come back after previous treatment) and is sensitive to medicines containing platinum.
YPOZANE 1,875 mg таблети за кучета YPOZANE 3,75 mg таблети за кучета YPOZANE 7,5 mg таблети за кучета YPOZANE 15 mg таблети за кучета
YPOZANE 1.875 mg tablets for dogs YPOZANE 3.75 mg tablets for dogs YPOZANE 7.5 mg tablets for dogs YPOZANE 15 mg tablets for dogs
Yrkesmässig bedömning bör användas vid bevakning av patientens behandlingssvar för att fastställa behovet för fortsatt behandling bortom 8 veckor eller utsättning av behandling om biverkningar skulle göra det befogat.
Professional judgement should be used in monitoring the patient’s response to therapy to determine the need for continued treatment beyond 8 weeks or discontinuation of treatment should adverse events warrant.
yrsel
feeling dizzy
Yrsel kan uppstå, vilket kan påverka förmågan att framföra fordon och använda maskiner (se avsnitt 4.8).
Dizziness may occur and this may have an effect on driving and use of machines (see section 4.8).
YTRACIS Итриев (90Y) хлорид
YTRACIS Yttrium (90Y) chloride
YTRACIS е радиофармацевтичен прекурсор.
YTRACIS is a radiopharmaceutical precursor.
YTRACIS не може да се прилага директно на пациенти.
Do not administer YTRACIS directly to the patient.
YTRACIS не може да се прилага директно на пациенти.
YTRACIS is not to be administered directly to the patient.
Ytterkartong
Outer carton
Ytterligare antibakteriella läkemedel ska användas när dessa patogener bidrar eller misstänks bidra till den infektiösa processen.
Additional antibacterial agents should be used when these pathogens are known or suspected to be contributing to the infectious process.
Ytterligare fas III-studier
Additional Phase III studies
Ytterligare information om denna produkt finns på Europeiska läkemedelsmyndighetens hemsida http://www.ema.europa.eu/.
Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/)
Ytterligare information om denna produkt finns tillgänglig på Europeiska läkemedelsmyndighetens hemsida http://www.ema.europa.eu/.
Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Ytterligare information om detta läkemedel finns på Europeiska läkemedelsmyndighetens webbplats http://www.ema.europa.eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Ytterligare information om detta läkemedel finns på Europeiska läkemedelsmyndighetens webbplats http://www.ema.europa.eu
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Ytterligare information om detta läkemedel finns på Europeiska läkemedelsmyndighetens webbplats http://www.ema.europa.eu.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Ytterligare information om detta läkemedel finns på Europeiska läkemedelsmyndighetens webbplats http://www.ema.europa.eu.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Ytterligare information om detta läkemedel finns på Europeiska läkemedelsmyndighetens webbplats http://www.ema.europa.eu.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Ytterligare information om detta läkemedel finns på Europeiska läkemedelsmyndighetens webbplats http://www.ema.europa.eu/
Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Ytterligare information om detta läkemedel finns på Europeiska läkemedelsmyndighetens webbplats http://www.ema.europa.eu/.
Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Ytterligare information om detta läkemedel finns på Europeiska läkemedelsmyndighetens webbplats http://www.ema.europa.eu/.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Ytterligare information om detta läkemedel finns på Europeiska läkemedelsmyndighetens webbplats http://www.ema.europa.eu/.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/
Ytterligare information om detta läkemedel finns på Europeiska läkemedelsmyndighetens webbplats: http://www.ema.europa.eu.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Ytterligare information om detta veterinärmedicinska läkemedel finns på Europeiska läkemedelsmyndighetens webbplats http://www.ema.europa.eu/
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
YTTRE KARTONG
OUTER CARTON
Yttre kartong, 8 mg, 16 mg, 32 mg och 64 mg
Outer carton 8mg, 16 mg, 32 mg and 64 mg
Yttriga е противопоказан в следните случаи:
Yttriga is contraindicated in the following cases:
Yttriga е противопоказан по време на бременност.
Yttriga is contraindicated in Pregnancy.
Yttriga е радиоактивно лекарство и се използва само в комбинация с друг лекарствен продукт.
Yttriga is a radioactive medicine and is only used in combination with another medicinal product.
Yttriga итриев (90Y) хлорид
Yttriga yttrium (90Y) chloride
Yttriga разтвор Итриев (90Y) хлорид
Yttriga solution Yttrium (90Y) chloride
Z 11 pacientů se u 2 rozvinula substituce M184V spojená s rezistencí na emtricitabin.
Among the 11 subjects, 2 developed the emtricitabine-associated resistance substitution M184V.
Z 333 pacientov s ovariálnym karcinómom, ktorí dostali trabektedín v kombinácii s PLD, 24 % bolo vo veku 65 rokov alebo starších a 6 % bolo starších ako 75 rokov.
Of the 333 patients with ovarian cancer who received trabectedin in combination with PLD, 24% were 65 years of age or older and 6% were over 75 years.
z antibiotikom, kot sta eritromicin ali klaritromicin, ki se uporabljata za zdravljenje okužb, ki jih
An antibiotic such as erythromycin, clarithromycin to treat infections caused by bacteria.
Z antiseptičnim zložencem obrišite predel kože, kamor boste injicirali zdravilo.
Wipe the injection site on the skin with an antiseptic wipe
Z biološkimi zdravili pa se je že zdravilo približno 11% bolnikov.
Approximately 11% of the patients had prior exposure to biologics.
Z dehidracijo in drisko se lahko poveča nevarnost ledvične toksičnosti zaradi cisplatina.
Dehydration and diarrhoea may increase the risk of renal toxicity for cisplatin.
Z in vitro Amesovim testom so ugotovili, da zdravilo Teysuno ni mutageno.
Teysuno was not found to be mutagenic when tested in the in vitro Ames assay.
Z mikrobiološkega stališča je potrebno zdravilo uporabiti takoj po odprtju.
From a microbiological point of view, the product should be used immediately.
Z mikrobiološkega stališča je treba raztopino uporabiti takoj, razen če postopek redčenja izključuje tveganje za kontaminacijo z mikrobi.
From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately.
Z mikrobiološkega stališča je treba raztopino za infundiranje uporabiti takoj po razredčenju.
From a microbiological point of view, the solution for infusion should be used immediately after dilution.
Z mikrobiološkega vidika je treba zdravilo uporabiti nemudoma.
From a microbiological point of view, the product should be used immediately.
Z močno prevelikimi odmerki ni kliničnih izkušenj.
There is no clinical experience with massive overdose.
Z nalepko označiti stekleničke po 10 in 30 ml
Label bottle 10 and 30 ml
Z nalepko označiti stekleničke po 150 ml
Label bottle 150 ml
Z o.o ul, Mogilska 80; 31-546 Krakow, Полша
Z o.o ul, Mogilska 80; 31-546 Krakow, Poland.
Z respiratorjem za novorojenčke s stalnim pretokom lahko to dosežete tako, da low flow zdravila INOmax potopite v inspiracijsko vejo napeljave respiratorja.
With a continuous flow neonatal ventilator, this may be achieved by infusing a low flow of INOmax into the inspiratory limb of the ventilator circuit.
Z tohoto důvodu by se měl před spaním užívat multivitaminový doplněk.
For this reason, a multivitamin supplement should be taken at bedtime.
Z těchto 692 pacientů bylo 613 (300 na atazanaviru s kobicistatem a 313 na atazanaviru s ritonavirem) na léčbě po dobu alespoň 48 týdnů a 496 (250 na atazanaviru s kobicistatem a 246 na atazanaviru s ritonavirem) bylo na léčbě po dobu alespoň 144 týdnů.
Of these 692 patients, 613 (300 atazanavir with cobicistat and 313 atazanavir with ritonavir) and 496 (250 atazanavir with cobicistat and 246 atazanavir with ritonavir) received at least 48 and 144 weeks of treatment, respectively.
Z urinom se izloči približno 51 % skupnega topotekana in 3 % N-desmetil topotekana.
Approximately 51 % was excreted as total topotecan and 3 % was excreted as N-desmethyl topotecan in the urine.
Z urinom se izloči približno 51 % skupnega topotekana in 3 % N-desmetil topotekana.
Approximately 51 % was excreted as total topotecan and 3% was excreted as N-desmethyl topotecan in the urine.
z zdravili za preprečevanje krvnih strdkov, kot so varfarin, fluindion, fenprokomon ali
Medicines to prevent blood clots, such as warfarin, fluindione, phenprocoumon or acenocoumarol (anticoagulants)
Z zdravjem povezana kakovost življenja
Health-related quality of life
Z zdravjem povezano kakovost življenja so ocenjevali z vprašalniki IBDQ in SF-36 (Short Form-36).
Health-related quality of life was assessed by IBDQ and SF-36 questionnaires.
Z zdravnikom se lahko dogovorite, da si boste zdravilo Stelara injicirali sami.
However, you and your doctor may decide that you may inject Stelara yourself.
Z zdravnikom se pogovorite o tem, kdaj boste prejemali injekcije in kdaj morate prihajati na kontrolne preglede.
Talk to your doctor about when you will have your injections and follow-up appointments.
Z.I. de Roubaix Est Rue de Toufflers 59390 Lys-Lez-Lannoy Франция
Z.I. de Roubaix Est Rue de Toufflers 59390 Lys-Lez-Lannoy France
Z.I. Limay-Porcheville 3 avenue Ozanne 78440 Porcheville Francija
Z.I. Limay Porcheville 3 avenue Ozanne 78440 Porcheville France
ZA (N = 1020)
ZA(N= 1020) ZA(N= 890) ZA(N= 951)
Za bolnike na hemodializi ni farmakokinetičnih podatkov.
No pharmacokinetic data in haemodialysis patients are available.
Za bolnike z blago do zmerno okvaro ledvic so priporočljivi nižji odmerki zoledronske kisline (glejte poglavje "Odmerjanje" zgoraj in poglavje 4.4).
In patients with mild to moderate renal impairment, reduced zoledronic acid doses are recommended (see section “Posology” above and section 4.4).
Za bolnike z metastazami v kosteh, ki imajo pred začetkom zdravljenja blago do zmerno okvaro ledvic, ki je za to populacijo bolnikov opredeljena kot CLcr 30–60 ml/min, so priporočljivi naslednji odmerki zdravila Zoledronska kislina Actavis (glejte tudi poglavje 4.4):
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30-60 ml/min, the following Zoledronic acid Actavis dose is recommended (see also section 4.4):
za bolnike, zdravljene z zdravilom Pravafenix 40 mg/160 mg ali pravastatinom 40 mg enkrat dnevno
for patients treated with Pravafenix 40 mg/160 mg or Pravastatin 40 mg once daily
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
For a full list of excipients, see 6.1.
Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
For a full list of excipients, see section 6.1.
Za dodatne informacije o injiciranju zdravila Stelara glejte poglavje ‘Navodilo za injiciranje zdravila’ na koncu tega navodila.
For instructions on how to inject Stelara, see ‘Instructions for administration’ at the end of this leaflet.
Za dodatne previdnostne ukrepe pri ravnanju z zdravilom glejte poglavje 6.6.
For further instructions on preparation and special precautions for handling, see section 6.6.
Za ekstravazacijo pemetrekseda ni specifičnega antidota.
There is not a specific antidote for extravasation of pemetrexed.
Za endotraheopulmonalno uporabo.
For endotracheopulmonary use.
Za enkratno uporabo, vso neporabljeno raztopino zavrzite.
Single use only, any unused solution should be discarded.
Za enkratno uporabo, vso preostalo raztopino zavrzite.
Single use only, any unused solution should be disposed of.
Za folinsko kislino je znano, da povečuje aktivnost snovi 5-FU, zato se priporoča previdnost.
Caution is advised as folinic acid is known to enhance the activity of 5-FU.
Za informacije o pediatrični uporabi glejte poglavje 4.2.
Please see section 4.2 for information on paediatric use.
Za informacije o rekonstituciji in redčenju zdravila Pemetreksed Hospira pred uporabo glejte poglavje 6.6.
For instructions on reconstitution and dilution of Pemetrexed Hospira before administration, see section 6.6
Za informacije o roku uporabnosti rekonstituiranega zdravila preberite navodilo za uporabo.
Read the package leaflet for the shelf life of the reconstituted product
Za intravensko odmerjanje glejte poglavje 4.2 povzetka glavnih značilnosti zdravila STELARA 130 mg koncentrat za raztopino za infundiranje.
For the posology of the intravenous dosing regimen, see section 4.2 of the STELARA 130 mg Concentrate for solution for infusion SmPC.
Za intravensko uporabo
For intravenous use
Za intravensko uporabo
Intravenous use
Za intravensko uporabo po rekonstituciji.
Intravenous use, after dilution.
Za intravensko uporabo.
For intravenous use.
Za intravensko uporabo.
Intravenous use
Za nadaljnje informacije glejte navodilo za uporabo.
See leaflet for further information
Za nadaljnje informacije o tem zdravilu se lahko obrnete na lokalno predstavništvo imetnika dovoljenja za promet z zdravilom:
For any information over this medicine, please contact the local representative of the Marketing Authorisation Holder: